90 students experience bioprinting at Fluicell

We at Fluicell are passionate about research and science and always want to take the opportunity to inspire…

Read more
08 May 2023

Capital Markets Day, May 22

We invite you to participate in our Capital Markets Day for a look into Fluicell’s development and future…

Read more
05 May 2023

Bioprinted liver model application note

The liver plays a central role during drug development because of its function in drug metabolization. Having an…

Read more
26 Apr 2023

Årsstämma 2023

Aktieägarna i Fluicell AB (publ), org. nr 556889-3282, (”Bolaget”) kallas härmed till årsstämma onsdagen den 17 maj 2023…

Read more
17 Apr 2023

Fluicell CEO Newsletter 01, 2023

We at Fluicell have had an exciting start to this year, with advances across all three business areas….

Read more
11 Apr 2023

Dynaflow Resolve used in reserach showing potential new ways to treat pain

Chronic pain is a condition that affects approximately 20 percent of the adult population. Today, poor efficacy and…

Read more
31 Mar 2023

A new era for Dynaflow Resolve

We are excited to announce the relaunch of our high-precision ion channel screening platform Dynaflow® Resolve. With Dynaflow…

Read more
23 Mar 2023

Fluicell makes in vitro development progress in type 1 diabetes therapeutics program

Fluicell’s R&D team is demonstrating important progress in the Company’s type 1 diabetes therapeutics in vitro development and…

Read more
16 Mar 2023

Fluicell at TERMIS-EU in Manchester

We look forward to meeting everyone in the tissue engineering and regenerative medicine community in Manchester for TERMIS-EU…

Read more
14 Mar 2023